Revive Therapeutics Ltd. announced to clarify certain disclosures in its press release titled “Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19,” issued on December 29, 2021 that provided an update on the Company's U.S. Food & Drug Administration (FDA) Phase 3 clinical trial (the Study) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. As of December 29, 2021, there were approximately 700 subjects that participated in the enrollment period of the Study. In addition, the Company has begun the process to expand the Study's patient population in Turkey in collaboration with Delta Health, which will add research sites from the largest hospital group in Turkey, MLP Care and Istinye University.

The Company expects patient enrollment in Turkey to occur by mid-February and completion of the Study's enrollment in Q1-2022. The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.